bluuebunny/crossref_metadata_2025_split huggingface dataset:
Dalfampridine effects on cognition, fatigue, and dexterity
Authors: Korsen Melanie , Kunz Rhina , Schminke Ulf , Runge Uwe , Kohlmann Thomas , Dressel Alexander 
Published: November 2016

AbstractObjectivesDalfampridine exerts beneficial effects on walking ability in a subgroup of patients with multiple sclerosis (MS). These patients are termed “responders”. Here, we investigated whether the responder status with respect to mobility measures would determine whether dalfampridine treatment exerts a beneficial effect on other MS symptoms. We therefore assessed walking ability, upper limb function, cognition, fatigue, visual evoked potentials (VEPs), depression, and quality of life in patients before and after dalfampridine treatment.MethodsPatients with MS and impaired mobility were recruited. Maximal walking distance, timed 25 Foot Walk, nine hole peg test, paced auditory serial addition test (PASAT), fatigue severity scale (FSS), VEPs, Beck Depression Inventory (BDI), EuroQol five dimensional questionnaire, and quality of life visual analogue scale were determined before and after 12–14 days of dalfampridine treatment. Repeated measures analysis of variance was applied to determine the effect of dalfampridine treatment.ResultsOf the 34 patients who completed the study, 22 patients were responders and 12 patients nonresponders, according to their performance in mobility measures. Treatment effects for the entire patient cohort were observed for PASAT (p = .029) and BDI (p = .032). Belonging to the responder cohort did not predict the response to treatment in these tests. For the FSS, response to dalfampridine treatment was dependent on the responder status (p = .001) while no effects in the total patient cohort were observed (p = .680). Other neurological functions remained unaltered. For VEP latencies, no significant improvements were detected.ConclusionIn this study, we observed beneficial effects of dalfampridine on cognition, depression, and fatigue. These effects were not limited to patients who responded to dalfampridine with improved mobility measures. These findings underscore the need to assess the beneficial effects of dalfampridine on neurological deficits in MS patients in additional randomized clinical trials.
Tunable particles alter macrophage uptake based on combinatorial effects of physical properties
Authors: Garapaty Anusha , Champion Julie A. 
Published: November 2016

AbstractThe ability to tune phagocytosis of particle‐based therapeutics by macrophages can enhance their delivery to macrophages or reduce their phagocytic susceptibility for delivery to non‐phagocytic cells. Since phagocytosis is affected by the physical and chemical properties of particles, it is crucial to identify any interplay between physical properties of particles in altering phagocytic interactions. The combinatorial effect of physical properties size, shape and stiffness was investigated on Fc receptor mediated macrophage interactions by fabrication of layer‐by‐layer tunable particles of constant surface chemistry. Our results highlight how changing particle stiffness affects phagocytic interaction intricately when combined with varying size or shape. Increase in size plays a dominant role over reduction in stiffness in reducing internalization by macrophages for spherical particles. Internalization of rod‐shaped, but not spherical particles, was highly dependent on stiffness. These particles demonstrate the interplay between size, shape and stiffness in interactions of Fc‐functionalized particles with macrophages during phagocytosis.
Heterologous expression and purification of active L‐asparaginase I of Saccharomyces cerevisiae in Escherichia coli host
Authors: Santos João H. P. M. , Costa Iris M. , Molino João V. D. , Leite Mariana S. M. , Pimenta Marcela V. , Coutinho João A. P. , Pessoa Adalberto , Ventura Sónia P. M. , Lopes André M. , Monteiro Gisele 
Published: November 2016

l‐asparaginase (ASNase) is a biopharmaceutical widely used to treat child leukemia. However, it presents some side effects, and in order to provide an alternative biopharmaceutical, in this work, the genes encoding ASNase from Saccharomyces cerevisiae (Sc_ASNaseI and Sc_ASNaseII) were cloned in the prokaryotic expression system Escherichia coli. In the 93 different expression conditions tested, the Sc_ASNaseII protein was always obtained as an insoluble and inactive form. However, the Sc_ASNaseI (His)6‐tagged recombinant protein was produced in large amounts in the soluble fraction of the protein extract. Affinity chromatography was performed on a Fast Protein Liquid Chromatography (FPLC) system using Ni2+‐charged, HiTrap Immobilized Metal ion Affinity Chromatography (IMAC) FF in order to purify active Sc_ASNaseI recombinant protein. The results suggest that the strategy for the expression and purification of this potential new biopharmaceutical protein with lower side effects was efficient since high amounts of soluble Sc_ASNaseI with high specific activity (110.1 ± 0.3 IU mg−1) were obtained. In addition, the use of FPLC‐IMAC proved to be an efficient tool in the purification of this enzyme, since a good recovery (40.50 ± 0.01%) was achieved with a purification factor of 17‐fold. © 2016 American Institute of Chemical Engineers Biotechnol. Prog., 33:416–424, 2017
The Work–Home Interface: Linking Work‐Related Wellbeing and Volunteer Work
Authors: Brauchli Rebecca , Peeters Maria C.W. , van Steenbergen Elianne F. , Wehner Theo , Hämmig Oliver 
Published: November 2016

AbstractAn abundance of research shows the benefits of participation in volunteer work for individuals, employers and the society as a whole. However, relatively little is known about the precursors of volunteer work. In this study, we aim to fill this gap by investigating to what extent work‐related well‐being can function as a driver of volunteer work. Moreover, building on the Conservations of Resources Theory (Hobfoll, , ), we propose that the relationship between work‐related well‐being (burnout and engagement) and volunteer work is mediated by the work–home interface (work–home enrichment and work–home conflict). This hypothesis was tested in a large Swiss sample (N = 1947). Consistent with our expectations, structural equation analyses revealed an indirect relationship between (i) work engagement and volunteer work via work–home enrichment and (ii) between burnout and volunteer work via work–home conflict. In conclusion, it seems that well‐being at work indeed functions as a precursor for volunteer work because of the consequences it has for the work–family interface. Copyright © 2016 John Wiley & Sons, Ltd.
MicroRNA‐383 is a tumor suppressor in human lung cancer by targeting endothelial PAS domain‐containing protein 1
Authors: Ma Hongjing , Liu Bin , Wang Shuoying , Liu Jing 
Published: November 2016

Lung cancer is the deadliest of all human cancers worldwide. The role of microRNA (miR)‐383 has been controversial in the initiation and progression of different cancers. We aimed to investigate the function of miR‐383 in human lung cancer both in vitro and in vivo. MicroRNA‐383 levels were analyzed in noncancerous versus cancerous human lung tissues and in normal versus lung cancer cell lines. Effect of miR‐383 on cell migration and invasion was examined in vitro and on tumor growth by using a xenograft mouse model in vivo. Potential mRNA target of miR‐383 was predicted, and underlying mechanism was explored as well. MicroRNA‐383 was downregulated in lung cancer tissue and cell lines. Expression of miR‐383 inhibited migration and invasion of human lung cancer cell lines in vitro and tumorigenesis of lung cancer xenografts in vivo. MicroRNA‐383 directly targeted 3′ untranslated region of endothelial PAS domain‐containing protein 1 (EPAS1) messenger RNA and inhibited both its mRNA and protein expressions. Reintroduction of EPAS1 could bypass the inhibition by miR‐383 on tumorigenesis of human lung cancer cell lines. MicroRNA‐383 is a tumor suppressor in human lung cancer by inhibiting EPAS1, both of which could serve as potential therapeutic targets in the treatment of lung cancer.Significance of the studyMicroRNA‐383 is a tumor suppressor in human lung cancer, which functions to inhibit tumorigenesis of lung cancer cells both in vitro and in vivo. This inhibitory effect is mediated by direct targeting of EPAS1 mRNA and subsequent repressing of its expression. Both microRNA‐383 and EPAS1 could serve as potential therapeutic targets in the treatment of lung cancer.
DNA Interstrand Crosslinks by H‐pin Polyamide (S)‐seco‐CBI Conjugates
Authors: Guo Chuanxin , Asamitsu Sefan , Kashiwazaki Gengo , Sato Shinsuke , Bando Toshikazu , Sugiyama Hiroshi 
Published: November 2016

AbstractAlthough DNA interstrand crosslinking (ICL) agents are widely used as antitumor drugs, DNA sequence‐specific ICL agents are quite rare. In this study, H‐pin imidazole‐pyrrole polyamide 1‐(chloromethyl)‐2,3‐dihydro‐1H‐benzo[e]indol‐5‐ol (seco‐CBI) conjugates that produce sequence‐specific DNA ICLs were designed and synthesized. Conjugates with H‐pin polyamide and seco‐CBI moieties were constructed to recognize a 7 bp DNA sequence, and their reactivity and selectivity in DNA alkylation were evaluated by using high‐resolution denaturing gel electrophoresis and sequence‐specific plasmid cleavage. One conjugate (6), which contained a chiral (S)‐seco‐CBI, exhibited greater sequence‐specific ICL activity toward the target DNA sequence and was cytotoxic to a cancer cell line. Molecular modeling studies indicated that the greater activity of 6 resulted from the relative orientation of the cyclopropane group in the (S)‐CBI unit.
Design of S‐Allylcysteine in Situ Production and Incorporation Based on a Novel Pyrrolysyl‐tRNA Synthetase Variant
Authors: Exner Matthias P. , Kuenzl Tilmann , To Tuyet Mai T. , Ouyang Zhaofei , Schwagerus Sergej , Hoesl Michael G. , Hackenberger Christian P. R. , Lensen Marga C. , Panke Sven , Budisa Nediljko 
Published: November 2016

AbstractThe noncanonical amino acid S‐allyl cysteine (Sac) is one of the major compounds of garlic extract and exhibits a range of biological activities. It is also a small bioorthogonal alkene tag capable of undergoing controlled chemical modifications, such as photoinduced thiol‐ene coupling or Pd‐mediated deprotection. Its small size guarantees minimal interference with protein structure and function. Here, we report a simple protocol efficiently to couple in‐situ semisynthetic biosynthesis of Sac and its incorporation into proteins in response to amber (UAG) stop codons. We exploited the exceptional malleability of pyrrolysyl‐tRNA synthetase (PylRS) and evolved an S‐allylcysteinyl‐tRNA synthetase (SacRS) capable of specifically accepting the small, polar amino acid instead of its long and bulky aliphatic natural substrate. We succeeded in generating a novel and inexpensive strategy for the incorporation of a functionally versatile amino acid. This will help in the conversion of orthogonal translation from a standard technique in academic research to industrial biotechnology.
Long non‐coding RNA MIAT knockdown promotes osteogenic differentiation of human adipose‐derived stem cells
Authors: Jin Chanyuan , Zheng Yunfei , Huang Yiping , Liu Yunsong , Jia Lingfei , Zhou Yongsheng 
Published: November 2016

AbstractRecently, long non‐coding RNAs (lncRNAs) have emerged as critical players in gene regulation for multiple biological processes. However, their roles and functions in human adipose‐derived stem cells (hASCs) differentiation remain unclear. In the present study, we investigated the role of lncRNA myocardial infarction‐associated transcript (MIAT) in the osteogenic differentiation of hASCs. We found that the expression of MIAT was downregulated in a time‐dependent manner during hASCs osteoinduction. MIAT knockdown promoted osteogenic differentiation of hASCs both in vitro and in vivo. Moreover, MIAT expression was increased upon tumor necrosis factor‐α treatment and MIAT knockdown reversed the negative effects of inflammation on osteoblastic differentiation. This study improves our knowledge of lncRNAs in governing the osteogenic differentiation of hASCs and may provide novel therapeutic strategies for treating bone diseases.
Long‐term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting
Authors: Wimmer Neil J. , Dufour Alyssa B. , Cho Kelly , Gagnon David R. , Quach Lien , Ly Samantha , Do Jacquelyn‐My , Ostrowski Simon , Michael Gaziano J. , Faxon David P. , Kinlay Scott 
Published: November 2016

ObjectivesTo assess the impact of stent type on the risk of death or myocardial infarction (MI) related to dual antiplatelet therapy (DAPT) more than 12 months (prolonged DAPT) versus 12 or less months after PCI for an acute coronary syndrome (ACS).BackgroundThe recent DAPT study reported lower recurrent ischemic events from prolonged DAPT in patients treated with PCI for an ACS, but was underpowered to determine the impact of stent type.MethodsWe determined clinical outcomes after PCI for an ACS (median follow‐up: DES = 26 months, BMS = 46 months) in 18,484 patients in the Veterans Affairs system treated with first generation drug‐eluting stents (DES) or bare‐metal stents (BMS). We used landmark analyses starting 1 year after the index PCI to assess the risk of prolonged DAPT on the primary endpoint of death or MI. Multivariable and propensity models adjusted for confounding.ResultsThere was a significant interaction between stent type and prolonged DAPT for death and MI (P = 0.0036), death (P = 0.054), and major bleeding (P = 0.0013). Patients treated with prolonged DAPT had lower risks of death or MI (HR = 0.71, 95% CI = 0.61, 0.82) and death (HR = 0.74, 95%CI = 0.62, 0.89) with DES, but not BMS, and higher risks of major bleeding, particularly with BMS (HR = 1.67, P < 0.001) than DES (HR = 1.24, p = 0.01).ConclusionsProlonging DAPT more than 12 months after PCI for ACS only associated with a lower risk of ischemic events in the 1–4 years after PCI in those receiving first generation DES. Stent type may influence the benefit of prolonged DAPT. © 2016 Wiley Periodicals, Inc.
Proximal balloon occlusion versus distal filter protection in carotid artery stenting: A meta‐analysis and review of the literature
Authors: Omran Jad , Mahmud Ehtisham , White Christopher J. , Aronow Herbert D. , Drachman Douglas E. , Gray William , Abdullah Obai , Abu‐Fadel Mazen , Firwana Belal , Mishkel Gergory , Al‐Dadah Ashraf S. 
Published: November 2016

IntroductionCarotid artery stenting (CAS) is typically performed using embolic protection devices (EPDs) as a means to reduce the risk of procedure‐related stroke. In this study, we compared procedural morbidity and mortality associated with distal (D‐EPD) vs. proximal (P‐EPD) protection.MethodsMEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were queried from January 1998 through May 2015. Only studies comparing (D‐EPD) and (P‐EPD) were included. Two independent reviewers selected and appraised studies and extracted data in duplicate. Random‐effects meta‐analysis was used to pool outcomes across studies. Heterogeneity of treatment effect among studies was assessed using the I2 statistics. Publication bias was assessed using inspection of funnel plots. The primary endpoints included 30‐day mortality and stroke. Secondary endpoints included new cerebral lesions on diffusion‐weighted magnetic resonance imaging (DW‐MRI) and contralateral lesions on DW‐MRI.ResultsA total of 12,281 patients were included from 18 studies (13 prospective and 5 retrospective) comparing (D‐EPD) and (P‐EPD) in the setting of CAS. The mean patient age was 69 years and 64% of patients were male. No evidence of publication bias was detected. There was no significant difference between the two modalities in terms of the risk of stroke (risk difference [RD] 0.0, 95% confidence interval [CI] −0.01 to 0.01) or mortality (RD 0.0, 95% CI −0.01 to 0.01) nor was there any difference in the incidence of new cerebral lesions on DW‐MRI or contralateral DW‐MRI lesions.ConclusionsIn patients undergoing CAS, both D‐EPD and P‐EPD provide similar levels of protection from peri‐procedural stroke and 30 days mortality. © 2016 Wiley Periodicals, Inc.
Novel use of the medtronic micro vascular plug for PDA closure in preterm infants
Authors: Wang‐Giuffre Elizabeth W. , Breinholt John P. 
Published: November 2016

ObjectivesTo describe a single institution experience with a new endovascular occlusion device used for transcatheter patent ductus arteriosus (PDA) closure in preterm infants.BackgroundThe PDA is a defect largely treated via cardiac catheterization except for the smallest patients.MethodsMedical records and catheterization reports of all premature neonates who underwent PDA device closure with the Medtronic Micro Vascular Plug (MVP) (Medtronic, Minneapolis, MN) between September 2015 and June 2016 were reviewed. Procedural details, complications, and short term outcomes were recorded.ResultsEight premature neonates born at a median gestational age of 28 weeks (23 to 35 weeks) underwent PDA closure with a Medtronic MVP. All devices were deployed via a 4F angled Glide catheter in prograde fashion without arterial access. Median age and weight was 52 days (15–112 days) and 2,550 g (1,800–3,500 g), respectively. Fluoroscopy and echocardiography were utilized for the procedure. Complete closure was achieved in all patients with no procedural complications, pulmonary artery or aortic obstruction or death. One device embolized 9 days after deployment and was successfully retrieved.ConclusionsThis study describes transcatheter PDA closure with the Medtronic MVP. The major advantage is the ability to deliver the device via a standard catheter in prograde fashion, and avoid the hemodynamic instability produced by rigid delivery sheaths. It also further validates the ability to close the PDA without arterial access, providing improved access to this procedure to smaller and more vulnerable children. © 2016 Wiley Periodicals, Inc.
Effect of post‐primary percutaneous coronary intervention bivalirudin infusion on net adverse clinical events and mortality: A comprehensive pairwise and network meta‐analysis of randomized controlled trials
Authors: Shah Rahman , Matin Khalid , Rogers Kelly C. , Rao Sunil V. 
Published: November 2016

ObjectiveTo compare the efficacies of various post‐percutaneous coronary intervenetion (PCI) bivalirudin doses on net adverse clinical events (NACEs) and mortality.BackgroundIn primary PCI, lower risk of bleeding with bivalirudin (vs. unfractionated heparin [UFH]) is counterbalanced by an increased risk of acute stent thrombosis (ST). Several randomized clinical trials (RCTs) and a recent meta‐analysis suggest that acute ST risk may be eliminated without compromising the bleeding benefit, but only if the full dose, not a low dose, of bivalirudin is continued post‐PCI. However, it is not known whether this improved risk leads to lower rates of NACEs and mortality.MethodsScientific databases and Web sites were searched for RCTs. Trials were included if study patients were undergoing primary PCI for acute ST‐segment elevation myocardial infarction and were randomly assigned to bivalirudin or UFH treatment. The bivalirudin arm was divided based on post‐PCI bivalirudin dosage: The Biv‐Full group received 1.75 mg/kg/h, the Biv‐Low group, 0.25 mg/kg/h, and the Biv‐No group, none.ResultsSix RCTs involving 16,842 patients were found. In pairwise meta‐analysis, bivalirudin improved 30‐day all‐cause mortality by 35% and cardiac mortality by 32%, but did not yield a NACE rate better than that achieved with UFH. Subgroup analysis showed the Biv‐Full group had a 46% lower NACE rate and 47% lower all‐cause mortality than UFH. These effects were not seen in the other two groups. Network meta‐analysis yielded similar results. At treatment ranking, the Biv‐Full group yielded the best treatment efficacy.ConclusionsIn primary PCI, full‐dose bivalirudin infusion for 3‐4 hr after PCI appeared to improve NACE rates compared to UFH. It also seemed to be the most effective strategy for improving cardiac mortality and all‐cause mortality. © 2016 Wiley Periodicals, Inc.
Evaluation of AgPd Nanoshells in Dual Catalysis: One‐Pot Silane Oxidation and Reduction of Organic Compounds
Authors: Kisukuri Camila M. , Reis João L. M. S. , Rodrigues Thenner S. , Camargo Pedro H. C. , Andrade Leandro H. 
Published: November 2016

AbstractAgPd nanoshells (AgPd NSs) were used as dual catalysts for hydrogen production and reduction of organic compounds in a one‐pot protocol. AgPd NSs were very efficient catalysts for the reduction of several functional groups, including alkenes, alkynes, imines, nitro compounds, and azides. Excellent chemoselectivities were observed for α,β‐unsaturated ketones, esters, and cinnamonitrile. Also, deuterium‐labeled compounds were prepared by using D2O instead of H2O. A packed‐bed reactor containing the immobilized AgPd NSs in silica (AgPd/SiO2) was designed to be used in continuous‐flow conditions. An optimized flow system with AgPd NSs was able to give the desired compounds in high conversions with 30–60 min residence time (tR).
Scanning Electrochemical Microscopy and Voltammetric Investigation of Silver Nanoparticles Embedded within a Nafion Membrane
Authors: Pecchielan Giulia , Battistel Dario , Daniele Salvatore 
Published: November 2016

AbstractIn this paper, silver nanoparticles (AgNPs), incorporated in the poly(perfluorosulfonic) acid membrane Nafion 117, were fabricated by chemical reduction of the Ag+‐loaded membranes, using HCOH in a basic medium as reducing agent. The AgNP content within the membrane varied proportionally to the concentration of AgNO3used in the incorporation step of Ag+in the ion exchange. Information on size and density of the AgNPs within the matrix was obtained by SEM analysis. The size of the AgNPs varied between 10 and 20 nm, regardless of the AgNO3concentration used for their preparation, while AgNPs density was the higher, the greater the AgNO3concentration in the solution was. Information on the oxidation state of Ag in the AgNPs and their distribution and aggregation on the surface of the Nafion membranes were obtained by SECM measurements. The use of [Ir(Cl)6]3−and Ru(NH3)63+as redox mediators allowed establishing whether the AgNPs were interconnected to create nanochain networks to provide AgNPs‐loaded Nafion membranes with electronic conductivity. Moreover, combination of SECM and anodic stripping voltammetry allowed establishing the reactivity of the AgNP–Nafion composites in terms of AgIspecies released at the nanocomposite/solution interface. These aspects are relevant for the potential application of these AgNPs‐loaded membranes for antimicrobial protection purposes.
Dipole Moment Effect on the Electrochemical Desorption of Self‐Assembled Monolayers of 310‐Helicogenic Peptides on Gold
Authors: Gobbo Pierangelo , Antonello Sabrina , Guryanov Ivan , Polo Federico , Soldà Alice , Zen Federico , Maran Flavio 
Published: November 2016

AbstractThe front cover artwork is provided by Pierangelo Gobbo and Flavio Maran, University of Padova (Italy). The image highlights how the orientation of the dipole moment associated with helical peptides affects the electrodesorption potential of the corresponding self‐assembled monolayers. Read the full text of the Article at 10.1002/celc.201600573.
Nerve Gas Simulant Sensing by a Uranyl–Salen Monolayer Covalently Anchored on Quartz Substrates
Authors: Trusso Sfrazzetto Giuseppe , Millesi Salvatrice , Pappalardo Andrea , Tomaselli Gaetano A. , Ballistreri Francesco P. , Toscano Rosa Maria , Fragalà Ignazio , Gulino Antonino 
Published: November 2016

AbstractA uranyl complex monolayer that easily allows the optical detection of a nerve gas simulant, namely, dimethyl methylphosphonate, is reported. Both UV/Vis spectroscopy and photoelectron data confirm that the functional hybrid material coordinates a Lewis base by means of the P=O group, which interacts with the uranium equatorial site available for complexation.